Moderna Inc. ($MRNA) Stock Forecast: Up 5.6% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company recognized for its mRNA technology, primarily in vaccine development, with a bullish movement in the market today.

Why is Moderna Inc. going up?

MRNA stock is up 5.6% on Feb 25, 2026 14:52

• Despite concerns about Moderna's financial standing, the stock has shown a notable recovery in its share price, signaling growing investor confidence.
• Positive outlook in the options market for Moderna, evident by the majority of trades predicting favorable outcomes, aligns with the current upward trend of the stock.
• Moderna's recent announcement about the FDA's review of its new mRNA flu vaccine, following dispute resolutions, likely contributed to the optimistic market sentiment and stock price surge.
• Protalix Biotherapeutics' strong performance, reaching a new 52-week high, reflects the overall robustness in the pharmaceuticals and biotechnology sector, potentially bolstering investor trust in companies like Moderna.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

3 Reasons to Avoid MRNA and 1 Stock to Buy Instead

This article cautions investors against buying Moderna (MRNA) despite its recent stock surge, citing three main reasons: tumbling revenue, declining earnings per share (EPS), and a dropping free cash flow margin. The author suggests that due to these financial weaknesses and a negative outlook for future profitability, investors should consider other, more stable industrial stocks instead of MRNA.

https://finviz.com/news/321335/3-reasons-to-avoid-mrna-and-1-stock-to-buy-instead

A Fresh Look At Moderna (MRNA) Valuation After A Sharp Share Price Rebound

Moderna (MRNA) has experienced a significant rebound in its share price recently, with a 15.0% 7-day return and 102.0% 90-day return, despite a 65.59% loss over five years. The company is considered undervalued by many, with a fair value estimated at $175.00 against a current price of $50.52. This optimistic valuation hinges on ambitious revenue growth and confident profit margins, though risks remain concerning its net loss and pipeline program success.

https://sg.finance.yahoo.com/news/fresh-look-moderna-mrna-valuation-081317235.html

What the Options Market Tells Us About Moderna

Whales have shown a bullish sentiment towards Moderna (NASDAQ: MRNA) in the options market, with 22 detected trades showing 45% bullish expectations and 36% bearish. The options activity suggests a price target range of $30.0 to $60.0 over the last three months, while current expert opinions set a consensus target price of $43.75 for the stock. Moderna's stock is currently trading up by 1.51% at $50.17, with RSI readings indicating it may be approaching an overbought condition.

https://www.benzinga.com/insights/options/26/02/50830121/what-the-options-market-tells-us-about-moderna

Moderna says FDA will consider its new flu shot after resolving public dispute

Moderna announced that the FDA will consider its new mRNA flu vaccine for approval, resolving a public dispute. The initial "refusal to file" by the FDA's vaccine chief, Dr. Vinay Prasad, was due to concerns about the clinical trial's scope regarding older adults. Moderna compromised by seeking full approval for adults aged 50-64 and accelerated approval for those 65 and older, with a commitment for a post-market study.

https://www.devilslakejournal.com/news/10769/moderna-says-fda-will-consider-its-new-flu-shot-after-resolving-public-dispute/

Protalix Biotherapeutics Hits New 52-Week High of $3.19

Protalix Biotherapeutics, Inc. has reached a new 52-week high of $3.19, reflecting strong performance in the pharmaceuticals and biotechnology sector. The company's stock price has increased by 163.87% over the past year, significantly outperforming the S&P 500. It maintains a price-to-earnings ratio of 27.00 and a market capitalization of $246 million.

https://www.marketsmojo.com/news/stocks-in-action/protalix-biotherapeutics-hits-new-52-week-high-of-319-3853885

Trending Today

XRP ($XRP) Crypto Forecast: Up 5.0% Today

Ethereum ($ETH) Crypto Forecast: Up 9.5% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.3% Today

Dogecoin ($DOGE) Crypto Forecast: Up 10.1% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 9.5% Today

CoStar Group Inc. ($CSGP) Stock Forecast: Down 8.8% Today

Workday Inc. ($WDAY) Stock Forecast: Up 10.0% Today

First Solar Inc. ($FSLR) Stock Forecast: Down 14.3% Today

Corning Incorporated ($GLW) Stock Forecast: Up 5.4% Today

Airbnb Inc. ($ABNB) Stock Forecast: Up 5.0% Today

Moderna Inc. Price History

11.01.2026 - MRNA Stock was down 9.3%

• A recent FDA decision on Moderna's flu vaccine application is seen as a setback for the company's vaccine pipeline, potentially influencing the bearish movement in the stock.
• However, the acceptance of mRNA-1010 for review in various regions such as the EU, Canada, and Australia may offer some comfort to investors, mitigating the overall impact on Moderna's financial prospects.
• The company's new five-year vaccine agreement with the Mexican government has the potential to counterbalance the negative sentiment from the FDA decision, indicating a strategic move for revenue growth and expansion into new markets.
• The market's response to Moderna's bearish trend today may reflect the varied reports on its vaccine developments and collaborations, with investors keen on monitoring the firm's regulatory advancements and commercial ventures in the future.

11.01.2026 - MRNA Stock was down 15.2%

• The FDA rejection of Moderna's flu vaccine application likely contributed to the bearish movement in MRNA stock. This setback could have raised concerns among investors about the company's pipeline and future revenue streams.
• Despite the FDA rejection, Moderna's strategic agreements with the Mexican government and local pharmaceutical companies could provide a potential revenue boost in the long term. However, the immediate market reaction seems to have been overshadowed by the negative news of the flu vaccine application rejection.
• The news of Moderna's acceptance for review in other regions like the EU, Canada, and Australia might have mitigated some of the stock's losses, indicating potential global market opportunities for the company.
• Overall, the market movement in MRNA today reflects a mix of regulatory challenges and strategic partnerships, showcasing the volatility and resilience of the biopharmaceutical sector.

20.01.2026 - MRNA Stock was up 8.3%

• The positive momentum in MRK stock could be linked to an upgraded Buy rating from Deutsche Bank with an increased price target. This optimistic forecast on the company's growth prospects, disregarding concerns about the Keytruda patent cliff, likely bolstered investor confidence.
• Furthermore, the FDA's approval of KEYTRUDA® and KEYTRUDA QLEX™ for a new indication affirmed Merck's market position, underscoring its dedication to developing groundbreaking treatments.
• Ongoing patent disputes and legal conflicts in the biotech sector, like BioNTech's lawsuit against Moderna for patent infringement regarding COVID shots, may have impacted market sentiment towards established players such as Merck, potentially generating heightened interest and investment in the company's stock.

23.01.2026 - MRNA Stock was up 6.0%

• Moderna experienced a strong bullish movement today due to multiple factors:
• Gilead Sciences' acquisition of Arcellx, focusing on CAR T-cell therapy, brought positive attention to the biotech sector and potentially increased investor confidence in similar companies like Moderna.
• The FDA's decision to review Moderna's mRNA flu vaccine and the initiation of the review for its investigational seasonal influenza vaccine submission (mRNA-1010) signaled progress and potential future revenue streams for the company.
• Despite facing legal challenges related to patent infringement and mixed financial results, including declining revenue, the positive developments with FDA reviews and vaccine submissions outweighed the concerns for investors.
• Telemark Asset Management LLC's significant acquisition of Moderna shares also indicated confidence in the company's future prospects, contributing to the bullish movement.

24.01.2026 - MRNA Stock was down 6.5%

• The bearish movement in MRNA's stock today is linked to concerns over potential FDA actions on mRNA vaccines, causing uncertainty and regulatory hurdles for the company's future vaccine developments.
• The negative revenue outlook and financial challenges may have led to investor caution and selling pressure on the stock.
• Despite recent positive updates, such as regulatory approvals and strategic agreements, the market sentiment appears to have been influenced more by broader challenges and uncertainties facing Moderna, resulting in the bearish movement in the stock today.

19.01.2026 - MRNA Stock was up 5.6%

• Merck & Co., Inc. (MRK) is a pharmaceutical company recognized for its innovative healthcare solutions. Today, the stock saw significant bullish movement in the market.
• MRK upgraded to a Buy rating by Deutsche Bank with a higher price target, noting undervaluation despite Keytruda patent cliff concerns.
• FDA approval of KEYTRUDA® and KEYTRUDA QLEX™ for a new indication strengthened investor confidence in the company's growth prospects.
• Positive developments regarding MRK outshined worries about the Keytruda patent cliff, leading to the stock's bullish market movement.
• Investor optimism towards MRK's future growth prospects and product portfolio expansion drove the market's positive reaction.

25.01.2026 - MRNA Stock was up 5.6%

• Despite concerns about Moderna's financial standing, the stock has shown a notable recovery in its share price, signaling growing investor confidence.
• Positive outlook in the options market for Moderna, evident by the majority of trades predicting favorable outcomes, aligns with the current upward trend of the stock.
• Moderna's recent announcement about the FDA's review of its new mRNA flu vaccine, following dispute resolutions, likely contributed to the optimistic market sentiment and stock price surge.
• Protalix Biotherapeutics' strong performance, reaching a new 52-week high, reflects the overall robustness in the pharmaceuticals and biotechnology sector, potentially bolstering investor trust in companies like Moderna.

18.01.2026 - MRNA Stock was up 9.5%

• Moderna faced setbacks in a patent dispute with Arbutus Biopharma, but the market remained bullish, indicating that investors are focusing more on the company's overall potential and developments in its vaccine pipeline.
• The FDA's decision to review Moderna's mRNA flu shot application, along with the positive results from the mid-stage trial of their combo flu/COVID vaccine, likely contributed to the bullish movement of the stock.
• Despite the ongoing legal challenges and regulatory hurdles, Moderna's innovative approach to vaccine development and the promising results of its trials seem to have instilled confidence in investors, driving the stock price up.

18.01.2026 - MRNA Stock was up 5.5%

• Optimism among investors was ignited by the FDA's decision to reassess Moderna's mRNA flu shot application after an initial rejection, potentially creating a new revenue source for the company.
• Despite uncertainties stemming from setbacks in the patent dispute with Arbutus Biopharma, investor focus on the flu vaccine review seemed to outweigh these concerns.
• Strong results from Moderna's combination flu/COVID vaccine trial further solidified investor confidence in the company's capabilities and future outlook, driving the bullish movement in stock price.
• Overall, market response to the FDA's review of Moderna's flu shot and encouraging vaccine trial outcomes indicates investor optimism about the company's ongoing success and innovation within the healthcare sector.

12.01.2026 - MRNA Stock was up 8.6%

• Moderna's stock experienced a strong bullish movement following the news of a five-year agreement with Mexico to enhance mRNA vaccine supply for respiratory diseases. This collaboration not only expands Moderna's market reach but also signifies its commitment to global health initiatives.
• The FDA's rejection of Moderna's flu vaccine application might have initially caused some uncertainty in the market. However, the positive development with Mexico and the focus on respiratory vaccines could have overshadowed this setback, driving the bullish momentum.
• The market seems to be reacting favorably to Moderna's strategic partnerships and long-term growth prospects, positioning the company as a key player in the biotech industry. Investors are likely viewing Moderna as a solid investment choice amidst ongoing advancements in medical technology and global health priorities.

13.01.2026 - MRNA Stock was up 7.3%

• Moderna experienced a strong bullish movement today as its sales beat expectations, driven by robust demand for its Covid-19 vaccine, which declined less than anticipated.
• The positive sales performance indicates that Moderna continues to play a significant role in the global vaccination efforts, contributing to its revenue growth.
• The market's reaction to Moderna's sales beat showcases investor confidence in the company's ability to navigate through changing demand dynamics for Covid-19 vaccines.
• The news of Moderna's sales exceeding estimates likely fueled investor optimism and contributed to the bullish movement in the stock price.

13.01.2026 - MRNA Stock was up 6.7%

• Moderna's stock experienced a bullish movement as the company exceeded fourth-quarter revenue expectations, driven by better-than-expected sales of its Covid vaccine.
• The positive outlook for Moderna can also be attributed to the overall market sentiment, with U.S. consumer prices rising less than anticipated, providing a boost to investor confidence.
• The increased capital injection into Jiuzi Holdings by multiple crypto investment institutions may have also contributed to a positive market sentiment, indirectly benefiting Moderna and other companies in the market.
• Analysts closely monitoring Moderna's performance amidst competition in the biotech space, particularly in the kidney disease portfolio and the expanding applications of its drugs, could have further fueled investor optimism in the stock.